Fiona H. Marshall’s Post

Our COO, Rudi Schmidt, will speak at the 15th Annual Drug Discovery Forum in Berlin about "What Real-World Data from #aging research can teach us for #AI-based precision medicine in #drug development." #Drugdevelopment faces high attrition rates, and the reproducibility and translatability of preclinical findings to human applications are still limited, resulting in a low return on investment in terms of clinical impact. In his presentation Rudi will focus on how to overcome these challenges and the translational discordance #realworlddata from research in aging and #longevity. Summarizing the latest publications he will outline several conclusions, for example, on state-of-the-art model-informed drug development (MIDD) that combines real-world data of physiology, pharmacology, and disease processes during aging with #artificialintelligence.   Decades of research using genetic and molecular biology tools have unlocked several hallmarks of aging. At the same time, our understanding of embryonic development and cell growth has considerably improved. The mechanisms and pathways related to aging can be targeted for lifestyle as well as for drug interventions. Now this knowledge has to be translated into drug development and clinical applications for age related diseases. 📆 Date: 4th & 5th September 2024 📍 Location: Hotel Palace Berlin (in person event) 🔗 Register https://lnkd.in/d8EFpTuh #DrugDiscovery #health #Innovation #DDIF2024

WEBINAR NEXT WEEK! Make sure you are signed up for this expert discussion with Dr Marcos Herrera Vaquero, Senior Scientist, and Thomas Brown, Senior Product Manager at bit․bio, on empowering motor neuron disease (MND) research and discovery programs with a new class of functional, reproducible human iPSC-derived motor neurons. A significant hurdle in MND discovery programs, particularly for conditions like amyotrophic lateral sclerosis (ALS), is the lack of consistent, physiologically relevant cells that accurately represent human biology in vitro. This challenge is underpinned by two key factors: the limited translatability of animal models and the long, complex, and difficult-to-scale differentiation protocols used in traditional methods to generate human iPSC-derived motor neurons. In this webinar, you will: 1. Gain insights into the challenges in identifying and developing new therapeutics for ALS and MND. 2. Understand how opti-ox™ powered ioMotor Neurons™ provide a defined and scalable solution for clump-free cell culture, making them easy to use in standard assays like patch clamp and cell imaging. 3. See characterisation data on the defined lower motor neuron identity and functional electrophysiology data on the formation of neuronal networks in astrocyte co-cultures. Register now: https://hubs.ly/Q02g-TjB0 #webinar #research #DrugDiscovery #launch #cell #optiox #ioCells #science #CellCulture #DrugDevelopment #MND #ALS #MotorNeurons #PatchClamp

C-Path is thrilled to welcome Wave Life Sciences as the newest member of its Duchenne Regulatory Science Consortium. Wave Life Sciences is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Wave’s diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Joining forces with Wave Life Sciences strengthens our collective commitment to advancing regulatory science in Duchenne muscular dystrophy research. Together, we're paving the way for innovative treatments and improved outcomes for patients. Welcome aboard, Wave Life Sciences! 👏 Ramona Belfiore-Oshan #CPath #DMD #globalhealth #drugdevelopment #datasharing #DuchenneResearch #Collaboration #Innovation #WaveLifeSciences

Organ-on-chip: research models for rare disease. Organ-on-chip research is an innovative and interdisciplinary field of study that focuses on developing microscale models of human organs and tissues on small chips or platforms to replicate their structure and function. These microscale devices play a role in advancing our understanding of cellular responses and interactions. Organs-on-chips serve as dynamic, biomimetic platforms that replicate the physiological conditions of specific organs, allowing for real-time observation of cellular behaviors. In the context of cell therapy, these platforms offer a valuable tool for testing and optimizing therapeutic interventions by closely mimicking the complexities of human organs. The chips typically contain microfluidic channels and chambers that simulate the physiological, mechanical, and biochemical conditions of specific organs.

#Translationalmedicine is an interdisciplinary field that combines #research findings with #clinicalpractice to develop new #diagnostictools, #therapies, and #preventivestrategies for #humandiseases. It aims to bridge the gap between #laboratorydiscoveries and #clinicalapplication, #improvingpatientoutcomes. By studying molecular and cellular mechanisms, it focuses on developing #personalizedtreatments for individual patients. Collaboration between #basicscientists, #clinicalresearchers, and #healthcareprofessionals drives the development of #innovativetherapies and enhances our understanding of #diseasepathogenesis. https://lnkd.in/de5ZfbZH

WEBINAR TOMORROW! Last call to join our expert discussion tomorrow on empowering motor neuron disease (MND) research and drug discovery with a new class of functional, reproducible human iPSC-derived motor neurons. Dr Marcos Herrera Vaquero, Senior Scientist, and Tom Brown, Senior Product Manager at bit․bio, will discuss how precision cell reprogramming technology is empowering scientists to advance research outcomes and improve drug discovery efficiencies for MND. In this webinar, you will: 1. Gain insights into the challenges in identifying and developing new therapeutics for ALS and MND. 2. Understand how opti-ox™ powered ioMotor Neurons™ provide a defined and scalable solution for clump-free cell culture, making them easy to use in standard assays like patch clamp and cell imaging. 3. See characterisation data on the defined lower motor neuron identity and functional electrophysiology data on the formation of neuronal networks in astrocyte co-cultures. Register now: https://hubs.ly/Q02hnM5J0 #webinar #research #DrugDiscovery #launch #cell #optiox #ioCells #science #CellCulture #DrugDevelopment #MND #ALS #MotorNeurons #PatchClamp

Don’t Miss This! Dive into the future of biomedicine with us next week in #SanDiego! Join us next week at the Festival of Biologics San Diego for an interesting panel discussion brought to you by Business Location Switzerland and Swissnex in San Francisco. What’s on the Agenda?  We’re diving deep into RNA technology and its role in developing breakthrough antibody therapies to fight critical illnesses such as cancer, Alzheimer's, and autoimmune diseases. Get ready to explore the latest trends, groundbreaking research, and the challenges ahead with top experts from both #Switzerland and the #US. Meet Our Esteemed Panelists: - Rudi Micheletti, spearheading Biology and Functional Genomics at Haya Therapeutics. - Susan Szathmary, MD, PhD, leading the charge at the Open Biopharma Research and Training Institute. - Dimitrios G. Zisoulis, the mind behind RNA Therapeutics at Johnson & Johnson. - Gene Yeo, a pioneering Professor at UCSD’s Dept of Cellular and Molecular Medicine and a key figure at the UCSD Institute for Genomic Medicine. The panel discussion "Decoding the Dark Genome through RNA Technology: Ways Forward with Swiss and US Innovation’” will be moderated by the insightful Julio de Unamuno IV, Executive Director of HomeLab at UCSD. Don’t miss out on this opportunity to gain insights from leading minds in the field and discover how Swiss and US expertise is paving the way forward in biotech innovation. #biotechnology #RNAtechnology #innovation #whyswitzerland #FestivalofBiologics #healthcare #pharma

Multiomics is advancing our understanding of cell biology and disease, paving the way for new diagnostics and targeted therapies. This fantastic article by Alison Halliday, PhD in Technology Networks highlights how multiomics, including epigenetics, is revolutionizing our understanding of biological mechanisms. The Omics Revolution: Multiomics and the Future of Biomedical Research 👉 https://lnkd.in/eyYSJSgX Dive deeper with our poster: Unlocking scalable and efficient multiomic analysis of 5‑ and 6‑base genomes 👉 https://lnkd.in/e_EhaqFz Adil Mardinoglu, Guillaume Pare, biomodal

The FDA modernisation act 2.0 is already fundamentally changing how drugs are developed and how their performance is translated from a laboratory environment to patients. Cell models that mimic parts of the complexity of the human body are developed by focused teams around the world and the space is driven by an incredible creativity. Yet, at the same time, cell biology has seen a limited evolution in the fundamental approaches of interacting with living cells. R&D processes are highly linear, a range of perturbations are uncontrolled if not random, and rarely captured in meaningful levels of detail. We are excited to share our latest perspective together with Dr. Julia Schueler from Charles River Laboratories on developing & deploying fit for purpose cell models through our sensor extended imaging workflow. Join the conversation and explore our Sensor Extended Imaging Workflow in our recent publication in Nature Communications Biology: https://lnkd.in/dPhmQ8Js Heikki Sjöman Carlo Kriesi #FDA2 #DrugDevelopment #CellBiology

Greetings once again from the other side of the screen! Gordian, like the ancient Greek concept of apeiron, continues to grow. We need your help to do so! Do you know someone with in vivo efficacy and development experience in any of the following indications: heart failure, MASH/NASH, osteoarthritis or pulmonary fibrosis? Please send this post to them. Are you said person? Then look no further! We are seeking multiple researchers at various levels (research associate -> principal) for preclinical development across our four indications. Gordian's team has built a Mosaic Screening platform that works in vivo, using the best animal models available. The platform is cranking out targets and we need the team that will validate and develop these hits as we move one step closer to patients. Principal/Senior Scientist (Preclinical Development) - Design and oversee experiments for validation and development, and lead the team’s operations across multiple core functions including histology and assays. https://lnkd.in/g3v6FVBF Scientist (Preclinical Development) - Architect and execute efficacy, biodistribution and toxicity experiments to evaluate the safety and mechanism of action of potential therapeutic targets. https://lnkd.in/ggEjuqgp In Vivo Scientist (Echocardiography) - Design and perform ultrasound studies on preclinical heart failure models as well as other essential preclinical research activities. https://lnkd.in/gJbgjJt9 Research Associate 2 (In Vivo) Manage vivarium operations, generate disease models, and execute complex in vivo assays and surgeries. https://lnkd.in/gFsQAsjH Read more about our values, including our most recent addition no. 6, here: https://lnkd.in/dJi9mdnK Thanks everyone!